Mineralys Therapeutics (Nasdaq: MLYS) announced inducement equity awards granted March 16, 2026, to a new non-executive employee under its 2025 Employment Inducement Incentive Award Plan.
The Compensation Committee granted a stock option for 27,920 shares and restricted stock units for 20,940 shares. Options vest over four years (25% after one year, then 1/48th monthly); RSUs vest 25% on each anniversary through four years. Grants were made as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MLYS
-2.76%
1 alert
-2.76%News Effect
On the day this news was published, MLYS declined 2.76%, reflecting a moderate negative market reaction.
Inducement stock options:27,920 sharesInducement RSUs:20,940 sharesOption vesting period:4 years+3 more
6 metrics
Inducement stock options27,920 sharesGranted to new non-executive employee under 2025 Employment Inducement Plan
Inducement RSUs20,940 sharesGranted to new non-executive employee under 2025 Employment Inducement Plan
Option vesting period4 years25% after one year from Mar 16, 2026; remainder monthly
RSU vesting schedule25% annually over 4 yearsOn each anniversary of Mar 16, 2026
Initial option cliff25%Vests on first anniversary of vesting commencement date
Ongoing option vesting1/48th monthlyAfter first anniversary, subject to continued service
Market Reality Check
Price:$25.02Vol:Volume 239,571 vs 20-day ...
low vol
$25.02Last Close
VolumeVolume 239,571 vs 20-day average 1,124,217 (relative volume 0.21), indicating subdued trading before this filing.low
TechnicalShares at $26.19, trading below the 200-day MA of $29.
Peers on Argus
MLYS was down 0.66% with mixed peer moves: IMVT -0.97%, SLNO -0.34%, CRNX -0.05%...
MLYS was down 0.66% with mixed peer moves: IMVT -0.97%, SLNO -0.34%, CRNX -0.05% lower while VKTX +0.93% and XENE +0.42% gained, pointing to stock-specific rather than sector-driven trading.
Corporate update on NDA filing and multiple positive lorundrostat trials.
Pattern Detected
Recent price reactions to news have mostly been modest and aligned with the tone of announcements, with one notable negative move on a routine inducement award.
Recent Company History
Over recent months, Mineralys has focused on lorundrostat’s regulatory and clinical progress, including FDA NDA acceptance with a PDUFA date of Dec 22, 2026 and detailed Explore‑OSA data. Routine items such as inducement equity awards and corporate updates have typically produced small price moves, while the NDA-related updates drew stronger positive reactions. Today’s inducement grant fits into a pattern of ongoing equity-based compensation alongside a broader NDA and commercialization trajectory.
Market Pulse Summary
This announcement details routine inducement equity awards—27,920 option shares and 20,940 RSUs—vest...
Analysis
This announcement details routine inducement equity awards—27,920 option shares and 20,940 RSUs—vesting over four years for a new non-executive employee under the 2025 inducement plan. Similar grants appeared repeatedly in recent months alongside larger milestones such as NDA acceptance and updated lorundrostat data. Investors may watch ongoing equity compensation trends, insider trading disclosures, and future regulatory updates to assess how ownership and incentives evolve relative to the company’s approval and commercialization path.
Key Terms
chronic kidney disease, ckd, obstructive sleep apnea, osa, +4 more
8 terms
chronic kidney diseasemedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
ckdmedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.
obstructive sleep apneamedical
"such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other"
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
osamedical
"such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other"
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
stock optionfinancial
"granted an inducement stock option award covering 27,920 shares and an inducement"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
restricted stock unitfinancial
"stock option award covering 27,920 shares and an inducement restricted stock unit award"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
equity awardsfinancial
"Plan, which provides for the granting of equity awards to new employees of Mineralys."
Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.
nasdaq listing rule 5635(c)(4)regulatory
"material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
AI-generated analysis. Not financial advice.
RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on March 16, 2026, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to a new non-executive employee.
The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The options will vest over a four-year period, with 25% of the total shares underlying the options vesting on the first anniversary of the award’s vesting commencement date, March 16, 2026, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The restricted stock units will vest over a four-year period, with 25% of the shares vesting on each of the four anniversaries of the award’s vesting commencement date, March 16, 2026. The awards were granted as an inducement material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Mineralys
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
What inducement awards did Mineralys Therapeutics (MLYS) grant on March 16, 2026?
The company granted a stock option for 27,920 shares and RSUs for 20,940 shares. According to the company, both awards were made under its 2025 Employment Inducement Incentive Award Plan as inducements for a new non-executive employee.
How do the Mineralys (MLYS) options vest that were granted March 16, 2026?
The options vest over four years with 25% vesting after one year and 1/48th vesting monthly thereafter. According to the company, vesting is subject to the employee’s continued service and starts March 16, 2026.
What is the vesting schedule for the Mineralys (MLYS) restricted stock units granted March 16, 2026?
The RSUs vest over four years with 25% vesting on each anniversary of March 16, 2026. According to the company, the schedule requires continued service for each annual vesting tranche to occur.
Under what plan were the inducement awards to Mineralys (MLYS) granted?
The awards were granted under the 2025 Employment Inducement Incentive Award Plan. According to the company, that plan authorizes equity awards to new employees as inducements to enter employment.
Why did Mineralys (MLYS) state the awards were granted under Nasdaq Rule 5635(c)(4)?
The company indicated the grants were made as an inducement material to a new employee joining the firm. According to the company, Nasdaq Listing Rule 5635(c)(4) permits such inducement grants for new hires.
